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Background: Many patients with IBS suffer on-going symptoms. The evidence base is poor for IBS drugs but they
are widely prescribed and advised in Guidelines. Cognitive Behavioural Therapy (CBT) can be helpful, but availability
is poor in the NHS. We developed a web-based CBT self-management programme (Regul8) in partnership with
patients and trialled it and common IBS medications in an exploratory factorial RCT to test trial procedures and
provide information for a larger trial.
Methods: Patients, 16 to 60 years, with IBS symptoms fulfilling Rome III criteria were recruited via GP practices and
randomised to over-encapsulated mebeverine, methylcellulose or placebo for 6 weeks and to 1 of 3 website
conditions: Regul8 with a nurse telephone session and email support, Regul8 with minimal email support, or no
website.
Results: 135 patients recruited from 26 GP practices. Mean IBS SSS score 241.9 (sd 87.7), IBS-QOL 64 (sd 20) at
baseline. 91% follow-up at 12 weeks. Mean IBS SSS decreased by 35 points from baseline to 12 weeks. There was
no significant difference in IBS SSS or IBS-QOL score between medication or website groups at 12 weeks, or in
medication groups at 6 weeks, or IBS-QOL in website groups at 6 weeks. However, IBS SSS at 6 weeks was lower in
the No website group than the website groups (IBS SSS no website =162.8 (95% CI 137.4-188.3), website 197.0
(172.4 - 221.7), Website + telephone support 208.0 (183.1-233.0) p = 0.037).
Enablement and Subjects Global Assessment of relief (SGA) were significantly improved in the Regul8 groups
compared to the non-website group at 12 weeks (Enablement = 0 in 56.8% of No website group, 18.4% website,
10.5% Website + support, p = 0.001) (SGA; 32.4% responders in No website group, 45.7% website group, 63.2%
website + support group, p = 0.035).
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Conclusions: This exploratory study demonstrates feasibility and high follow-up rates and provides information for
a larger trial. Primary outcomes (IBS SS and IBS QOL) did not reach significance at 6 or 12 weeks, apart from IBS SSS
being lower in the no-website group at 6 weeks - this disappeared by 12 weeks. Improved Enablement suggests
patients with access to the Regul8 website felt better able to cope with their symptoms than the non-website
group. Improved SGA score in the Regul8 groups may indicate some overall improvement not captured on other
measures.
Trial registration: ClinicalTrials.gov Identifier (NCT number): NCT00934973.
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Primary careBackground
Irritable bowel syndrome (IBS) is a common chronic
gastrointestinal disorder that affects 10 – 22% of the UK
population and costs the National Health Service (NHS)
over 200 million pounds a year [1,2]. Abdominal pain,
bloating and altered bowel habit affect quality of life, social
functioning and time off work [3,4]. Treatment relies on a
positive diagnosis, reassurance, lifestyle advice, and drug
and psychological therapies [5]. However, many patients
suffer on-going symptoms.
Bulking agents and antispasmodics are the most
commonly prescribed medications in the UK and Europe.
IBS Guidelines [3,5] and a Cochrane review [6] have
highlighted the lack of evidence for the current drug
management but still recommend them as first line
management in primary care. Most studies of anti-
spasmodics and bulking agents for IBS were undertaken a
long time ago, are of poor quality, with small numbers,
in a secondary care setting. Thus, neither doctors nor
patients have good evidence to inform prescribing decisions
in primary care which is where most patients are managed.
However, IBS drugs are recommended in the guidelines
[3,5] and very widely used. In 2005, NHS costs were
nearly £10 million for mebeverine and over £8 million
for fibre-based bulking agents (Prescription Cost Analysis
figures). Trials of mebeverine and a fibre-based bulking
agent would help to provide evidence to inform prescribing
decisions in IBS.
Psychological therapies, such as face to face Cognitive
Behavioural Therapy (CBT) have been shown to be helpful
for IBS (symptoms and global wellbeing) particularly in
the short term, though there is less evidence in the longer
term [5,7-11]. NICE Guidelines [5] state that there is good
evidence to show a significant global improvement in IBS
symptoms with CBT compared to no treatment. NICE
recommended psychological therapies for patients with
resistant IBS that has not responded to other measures
after 12 months. However, availability is very limited, CBT
in this format has not been proven to be cost effective
[12] and there are problems with high drop-out rates [12].
Web-based CBT has been shown to be helpful for otherconditions, e.g. depression [13] and tinnitus [14], insomnia
[15] and NICE has recommended the use of web-based
CBT for depression, panic and phobia in Primary Care
[16]. Thus, web-based CBT could be an efficient, cost
effective way of providing help to those with IBS. Despite
extensive literature searching before the start of this study,
we found no published evaluations of web-based CBT
programmes for IBS. A mindfulness study and a small
CBT study have since been published [17,18]. Development
and testing of a web-based CBT programme for IBS
has the potential to make CBT more widely available
for IBS with minimally increased costs. The increasing
availability of the internet makes this a good medium
to provide easily accessible patient information and
self-management programmes.
Aims
To undertake an exploratory factorial RCT to assess
the effectiveness of the prescribed medications in UK
general practice for IBS: mebeverine (an anti-spasmodic)
and methylcellulose (bulking-agent) against placebo, and
Regul8, a CBT self-management website for IBS developed
specifically for this study.
Methods
The study protocol has been published on BMC Gastro-
enterology providing a fuller description of the method
[19]. Full Ethical Approval was granted by Southampton
A Ethics committee: Reference number: 09/H0502/101.
Patients with IBS were identified by searching GPs’ lists
and by opportunistic recruitment of presenting patients.
Potential participants were sent a letter inviting them to
take part. GP practices in urban and rural settings
and differing socio-demographic characteristics were
included. Informed written consent was obtained from
all participants.
Inclusion criteria
Patients aged 16 to 60 years with symptoms of IBS
that fulfil Rome III criteria (maximum 60 years as
NICE guidelines advise that a new change in bowel
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tions [5]) Potentially eligible participants had screen-
ing bloods (full blood count (FBC), transglutaminase
antibodies (TTG) and a C-Reactive protein (CRP) to
exclude alternative diagnoses, i.e. anaemia and Coeliacs
disease).Exclusion criteria
Atypical symptoms – (unexplained weight loss or rectal
bleeding), diagnosis of inflammatory bowel disease,
coeliac disease or peptic ulcer disease, pregnant or
breast feeding, currently taking or allergy to mebeverine
or methylcellulose.Table 1 Summary of the Regul8 web-based self-management
Session 1: Understanding your IBS Rationale f
1. Possible
with the fu
2. How the
with the e
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Developm
Homework
conjunctio
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Behavioura
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The impor
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Homework
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Identifying
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throughouRegul8 self-management web-based programme
We developed a web-based CBT self-management
programme for IBS based on a paper-based manual
[20] originally developed and tested by one of our team in
a RCT in primary care (RMM) [20]. LifeGuide software
was used to develop the website [21]. As each web-based
module was developed, ‘Think Aloud’ [22] interviews were
undertaken with four patients with IBS to ensure that the
website was relevant, understandable, navigable and user
friendly. The feedback was used to modify the site during
development. The intervention consists of 8 sessions for
participants to work through over 6 weeks (see Table 1 for
an overview of each session) and includes interactive
components such as: development of a personal model,sessions
or self-management which includes the following explanations:
causes of IBS and illustrative physiology of the digestive system together
nctional changes that occur in the gut as a result of IBS.
autonomic nervous system (“fight-or-flight” stress system) may interact
nteric nervous system.
ent of the interaction between thoughts, feeling and behaviours and
can impact on stress levels and gut symptoms.
ent of a personal model of IBS which incorporates these elements.
: Daily diaries of the severity and experience of IBS symptoms in
n with stress levels and eating routines/behaviours.
the symptom diary.
l management of the symptoms of diarrhoea and constipation, and
yths in this area are discussed. Goal setting is explained.
tance of healthy, regular eating and not being overly focused on
is covered.
: Goal setting for managing symptoms and regular/healthy eating. Goal
nitoring and evaluation continue weekly throughout the programme.
e of exercise in symptom management is covered.
activity patterns such as resting too much in response to
or an all-or-nothing style of activity is addressed.
: Goal setting for regular exercise and managing unhelpful activity
relevant.
unhelpful thought (negative automatic thoughts) in relation to high
xpectations and IBS symptoms is introduced.
en these thoughts, feelings, behaviours and symptoms is reinforced.
: Goal setting plus daily thought records of unhelpful thoughts related
l expectations and patterns of over activity.
for coming up with alternatives to unhelpful thoughts are covered
ith personal examples.
: Goal setting plus daily thought records including coming up with
ernative thoughts.
management and sleep hygiene are discussed.
atic breathing, progressive muscle relaxation and guided imagery
are presented in video and audio formats.
: Goal setting for stress management, relaxation techniques and good
ts.
bility of flare-ups is discussed and patients are encouraged to develop
, long term goals and to continue to employ the skills they have learnt
t the manual to manage flare-ups and ongoing symptoms.
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Interactive components help users to remember advice,
reflect and provide a “substitute” for the therapist [23].
Tailoring feedback to users' symptoms, allows them to
focus on personally relevant aspects of the programme.
Early in each session participants review key points from
the previous session and review their homework, thereby
reinforcing previous learning.
Intervention
Patients were randomised to: mebeverine (135 mg three
times a day), methylcellulose (3 tablets twice a day), or a
placebo tablets for 6 weeks. To ensure double blinding, all
participants took three over-encapsulated identical tablets
in the morning, one at lunchtime and three at dinnertime.
They were also randomised to 1 of 3 website conditions:
access to Regul8 with a 30 minute nurse telephone session
(to encourage engagement with the CBT programme) and
email support on request; the website with minimal
support (i.e. technical email support on request), or no
website, thus creating 9 groups.
Baseline characteristics were collected by on-line
questionnaire including: gender, age, length of symptoms,
deprivation score, IBS type and educational level. All
patients received a telephone call in the first week to
check they had no problems with the medication or
paperwork. Those not randomised to website access
received standard patient information and were offered
website access at the end of the trial.
Telephone session
The telephone session in the ‘website with telephone
support’ group was scheduled after patients completed
session 2 where they develop their own personal model
of how their thoughts, feelings and behaviours might be
contributing to their IBS symptoms. The purpose of the
session was for the patients to clarify their model, to
help extend their model and to motivate patients to
continue using the website. To ensure treatment fidelity
one practice nurse delivered all the telephone sessions.
Prior to undertaking the sessions, the nurse received six
training sessions including a basic introduction to CBT
techniques. All telephone sessions were audio-taped.
RMM regularly listened to the tapes and provided
fortnightly supervision to the nurse during the trial.
Randomisation
A randomisation list was computer generated indepen-
dently of the research team. Participants were block
randomised in blocks of 9 and stratified by type of IBS
(i.e. diarrhoea predominant, constipation predominant,
alternating-pattern) as there might be a different response
to the medications between these sub-groups.Outcome measures
Primary outcome measures
Change in the Irritable Bowel Symptom Severity Scale
(IBS SSS score) [24] and IBS Quality of Life Questionnaire
(IBS-QOL) [25,26] from baseline to 12 weeks. Primary
outcome data were collected at baseline and 6 and
12 weeks post randomisation.
The rationale for including two primary outcome
measures is that IBS is a chronic relapsing/remitting
condition. It is both the severity of the symptoms in
themselves and the sufferer’s ability to manage and live
with the symptoms and their resultant quality of life
that are important. CBT may have a greater effect on
peoples’ ability to live with and manage their symptoms
than on the severity of the symptoms themselves so it is
particularly important to include quality of life as a main
outcome in studies such as this.Secondary outcome measures
Patient Enablement Questionnaire [27] (measured at 6
and 12 weeks), Subjects Global Assessment of Relief
(SGA of Relief ) [28] (measured at 12 weeks), Hospital
Anxiety and Depression Scale (HADS) [29] (measured at
baseline, 6 and 12 weeks). In SGA of relief participants
rate their relief from IBS symptoms on a scale of 1 to 5
ranging from "completely relieved" to "worse". Scores are
dichotomized; patients scoring from 1–3 are considered
responders, those 4–5, non-responders as has been
undertaken in previous studies [20,28]. Patient enable-
ment questionnaire [27] assesses participants’ ability to
cope with their illness and life based on 6 questions
scored 0 to 2.
Qualitative interviews were undertaken with 30
participants regarding their experience of participating in
the trial, the acceptability of the trial procedures, including
the medication taking and perceptions of the web-based
self-management programme. These results will be pre-
sented in a separate paper.
Sample size: The aim of this pilot was to have sufficient
numbers to assess both the feasibility of trial procedures
and to provide an estimate of the likely differences
between the groups. The previous trial of CBT in
primary care [8] demonstrated a 68 point reduction
in symptoms score (a standardised effect size of more
than 0.8). Assuming an initial mean symptom score
of 250 (SD 80) in all groups, 35 patients were required in
each group to detect a difference in score of 53
points (a moderate standardised effects size of 0.66)
between the treatment groups (mebeverine, methylcellulose
and placebo) or the three website groups (none, minimal
support, telephone) for 80% power and 95% confidence.
Allowing for drop outs at 20%, we estimated 130 partici-
pants would be needed. 135 patients facilitated similar
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the different modes of action of the interventions we
assumed no interaction between the website and medi-
cation interventions.
Statistical analyses
The statistical analyses were performed with SPSS. Data
screening showed that the assumptions of normality were
met for the distributions of all the variables except
for HADS depression subscale and Enablement scale.
Both sub-scales were divided in groups according toAssessed for El
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Recruitment
5715 invitation letters were sent from 26 GP practices to
patients on their practice lists with a diagnosis code for
IBS. 431 positive replies were received, 265 potential
participants completed on-line screening and167 were
eligible but 4 of these were excluded after screening blood
tests. 135 participants entered the trial (see Figure 1:
CONSORT Diagram).Decline to participate data
673 patients returned a reply slip declining to take part
in the study. Reported reasons for declining: 127 said
they did not have time in their daily schedule, 162 did
not wish to take medications, 33 were already taking
Mebeverine or Methylcelluose and did not wish to stop
them, 53 did not wish to take part in the self-management
programme, 366 said IBS symptoms had improved andTable 2 Randomised participants by website group
Variable Website only Web
N = 45
Age (years), mean (SD) 45.76 (9.21)
Length of symptoms (years), mean (SD) 10.51 (8.19)
Median (IQR) 10.00 (12.00)
IBS-SSS total, mean (SD) 237.33 (85.36) 2
IBS-QOL score, mean (SD) 67.32 (17.89)
HADS score for anxiety, mean (SD) 8.73 (3.40)
HADS score for depression, mean (SD) 4.20 (2.87)
Median (IQR) 4 (4)
Deprivation score, mean (SD) 12.27 (9.07)
Median (IQR) 10.06 (9.79)
Gender n (%)
Male 14 (46.7)
Female 31(29.5)
Type of IBS n (%)
Constipation 5 (38.5)
Diarrhoea 14 (34.1)
Mixed 26 (32.1)
Severity IBS on IBS SSS n (%)
Mild 10 (33.3)
Moderate 24 (32.4)
Severe 11 (35.5)
Education n (%)
No formal 2 (25.0)
GSCE/O 11 (31.4)
A level 11 (32.4)
Degree 12 (38.7)
Postgraduate 5 (33.3)
Other 4 (33.3)that they did not need additional help, 50 said they did
not know they had an IBS diagnosis, and 15 did not have
computer access. Patients could choose more than one
option for declining.
Follow–up
A total of 126/135 participants (93%) completed the six
week-follow up and 123/135 (91%) completed the twelve
week follow-up.
Compliance with Regul8
91 participants were allocated to either website alone or
website with support. The number of sessions undertaken
by participants ranged from 0 to 8 (all sessions), with 7
participants completing no sessions and 21 completing 8
sessions, the median was 4 sessions. Compliance was
defined as complying with 4 or more sessions. Overall, 51/
91 (56%) complied with the self-management programme.site with support No website Test
N = 45 N = 45
45.13 (10.13) 42.18 (11.48) F(2,132) = 1.524, p = 0.222
12.87 (9.47) 9.00 (8.14) KW, ap = 0.129
12.00 (15.00) 7.50 (8.75)
37.30 (100.78) 251.36 (75.92) F(2,132) = 0.377, p = 0.687
60.00 (3.13) 64.86 (19.39) F(2,132) = 1.65, p = 0.20
9.46 (3.91) 10.00 (4.12) F(2,132) = 1.23, p = 0.30
5.26 (3.68) 5.32 (3.56) KW, ap = 0.263
5 (6) 5 (5)
8.65 (5.54) 12.81 (9.40) KW, ap = 0.026*
6.57 (7.63) 9.79 (9.21)
12 (40.0) 4 (13.3) X2(2) = 6.844, p = 0.034*
34 (32.4) 40 (38.1)
X2(4) = 0.70, p = 0.953
5 (38.5) 3 (23.1)
13 (31.7) 14 (34.1)
28 (34.6) 27 (33.3)
12 (40.0) 8 (26.7) X2(4) = 1.37, p = 0.85
23 (31.1) 27 (36.5)
11 (35.5) 9 (29.0)
X2(10) = 3.65, p = 0.97
4 (50.0) 2 (25.0)
11 (31.4) 13 (37.1)
10 (29.4) 13 (38.2)
10 (32.3) 9 (29.0)
7 (46.7) 3 (20.0)
4 (33.3) 4 (33.3)
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28/46 (61%) randomised to the website plus telephone
support complied.Compliance with drugs
Compliance with medicine taking overall was 80% based
collection of medication boxes at the end of the trial
(data available for 91/135). Only 13/135 stopped taking
the medications (11%). We had expected some drop out
from medication taking considering the requirement to
take 7 over-encapsulated tablets daily for six weeks. 7/
13 of these participants stated they stopped the medication
because their IBS symptoms worsened. 6/13 did not give
a reason.Telephone sessions
40/46 (87%) participants in the website plus support
group received the support telephone session. Of the 6Table 3 Randomised participants by medicine group
Variable Mebeverine Me
N = 44
Age (years), mean (SD) 45.44 (7.73)
Length of symptoms(years) - mean (SD) 11.20 (8.94)
Median (IQR) 10.00 (11.00)
IBS-SSS total score - mean (SD) 270.02 (77.27) 2
IBS-QOL score - mean (SD) 59.58 (20.60)
HADS score for anxiety- mean (SD) 9.23 (4.02)
HADS score for depression - mean (SD) 5.76 (3.75)
Median (IQR) 6.00 (6.00)
Deprivation score, mean (SD) 12.19 (8.57)
Median (IQR) 10.06 (9.71)
Gender - n (%)
Male 12 (40.0)
Female 31 (29.5)
Type of IBS - n (%)
Constipation 5 (38.5)
Diarrhoea 13 (31.7)
Mixed 25 (30.9)
Severity IBSon IBS SSS n (%)
Mild 3 (10.0)
Moderate 26 (35.1)
Severe 14 (45.2)
Education - n (%)
No formal 4 (50)
GSCE/O 12 (34.3)
A level 10 (29.4)
Degree 8 (25.8)
Postgraduate 6 (40.0)
Other 3 (25.0)participants who did not receive the sessions, 3 declined
the invitation but continued working on the self-
management programme, 1 was not contactable but
continued working on the website, and 2 withdrew from
the trial after randomisation.Stratification by IBS type
This pilot trial showed that it was feasible to stratify
participants by IBS type (Constipation, Diarrhoea or Mix
pattern IBS) and that trial procedures worked well for
this. No statistical analysis by stratification was planned
for the pilot to as it was not powered for this. However,
a stated aim in the protocol was to examine the data
for any worsening of symptoms in the Diarrhoea
predominant IBS strata that received methylcellulose.
There was no evidence of increased dropouts or reported
adverse events, so there is no indication that this group
should be excluded from a larger trial.thylcellulose Placebo Test
N = 46 N = 46
43.52 (12.22) 44.24 (10.57) F(2,132) = 0.385, p = 0.68
10.30 (9.05) 10.91 (8.34) KW, ap = 0.783
8.50 (12.00) 10.00 (11.00)
33.15 (89.19) 224.35 (90.79) F(2,132) = 3.483, p = 0.034*
65.70 (18.64) 66.51 (19.49) F(2,132) = 1.65, p = 0.20
9.57 (4.19) 9.37 (3.30) F(2,132) = 0.84, p = 0.92
4.22 (4) 4.93 (3.25) KW, ap = 0.109
3.00 (4.00) 4.00 (6.00)
11.38 (8.87) 10.12 (7.52) KW, ap = 0.499
8.00 (9.56) 8.25 (7.26)
9 (30.0) 9 (30.0) X2(2) = 1.18, p = 0.57
37 (35.2) 37 (35.2)
3 (23.1) 5 (38.5) X2(4) = 0.893, p = 0.932
15 (36.6) 13 (31.7)
28 (34.6) 28 (34.6)
X2(4) = 11.48, p = 0.021*
11 (36.7) 16 (53.3)
27 (36.5) 21 (28.4)
8 (25.8) 9 (29.0)
3 (37.5) 1 (12.5) X2(10) = 5.67, p = 0.85
9 (25.7) 14 (40)
12 (35.3) 12 (35.3)
11 (35.5) 12 (38.7)
5 (33.3) 4 (26.7)
6 (50.0) 3 (25)
Figure 3 IBS symptom severity score at baseline, six and
twelve weeks by medicine group.
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The mean age of participants was 44 years, 78% were
women. The mean length of symptoms reported was
10.8 years (SD = 8.7). Mean IBS-SSS score at baseline
was 241.9 (SD = 87.7), which represents a moderate
severity of IBS. Baseline characteristics were similar
across the groups (please see Tables 2 and 3), with the
exception of Gender (X2 p = 0.034) and Deprivation
scores (KW p = 0.026) in the website conditions and
IBS-SSS total mean (Fp = 0.034) (also reflected in the
symptom severity classification (p = 0.021)) in the drug
conditions. We assessed these variables in the ANCOVA/
regression analyses. However, none were significant, so
they were not included in the models.
Primary outcomes
The mean of the IBS-SSS score of the whole sample
decreased (positive change) 52 points from baseline to
the 6 week point and 35 points from baseline to the
12 week point. The mean of the IBS-QOL score of the
sample increased (positive change) 6 points from base-
line to the 6 week point and 5 points from baseline to the
12 week point (Figures 2 and 3).
At 6 weeks there was no significant difference in IBS
SSS or IBS-QOL between the medicine groups or for
IBS-QOL for the website groups (see Tables 4 and 5).
However, there was a statistically significant difference
seen in the IBS SSS for the website, with the no website
group having a lower IBS SSS score than the website
groups (IBS SSS no website =162.8 (95% CI 137.4-188.3),
website 197.0 (172.4 - 221.7), Website + telephone support
208.0 (183.1-233.0) p = 0.037). This difference disappeared
by 12 weeks (see Figure 2 and Tables 4 and 6).Figure 2 IBS symptom severity score at baseline, six and
twelve weeks by website group.No significant difference was found between the
self-management website groups or the medicine groups
for the IBS SSS or quality of life at the twelve week follow
up. (see Tables 6 and 7 for summary statistics).
There was no evidence of interactions between the
medicine and website groups in any of the analyses.
The mean scores suggest improvements across all
groups particularly at the 6 week (end of treatment)
period (Tables 4 and 5). There was however a trend for
continued improvement in the self-management groups
(particularly those who had the telephone support)
whilst those in the no website group and the medication
groups appeared to lose some of these gains at 12 weeks
(see Figures 2 and 3 and Tables 6 and 7).Secondary outcomes
No significant difference was found in HADs, Enablement
or SGA between the medication groups or in the HADs
scores between the website groups (Tables 4 and 7). A
highly significant difference was found in the Enablement
scores at 6 and 12 week follow-up between the website
conditions and the control group (Tables 4 and 6).
The participants in the Website groups reported better
Enablement than the ones in the no website group.
The higher scores were found in the Website plus
support condition. This suggests that the participants
who had access to the website coped better with their IBS
symptoms than the control group.
A significant difference was also found in the SGA at
12 week follow-up between the website groups (Table 6).
The participants in the website groups had better scores
than the no website group, indicating that the participants
who had access to the website rated their overall IBS
Table 4 Main and secondary outcomes for website groups at six week follow up
Variable Website Website + support No website group Significance
IBS-SSS total mean (n = 123) 197.0 (172.4 - 221.7) 208.0 (188.1 - 233.0) 162.8 (137.4 -188.3) p = 0.037*
IBS-QOL score (n = 123) 71.6 (67.9-75.2) 67.6 (63.9-71.3) 69.4 (65.7-73.1) p = 0.315
HADS score for anxiety (n = 114) 8.9 (7.9-9.8) 9.7 (8.8-10.6) 8.3 (7.3-9.2) p = 0.109
HADS score for depression (n = 114) (%) p = 0.122
Normal (0–7) 35 (89.7) 28 (71.8) 31 (79.5)
Mild (8–10) 2 (5.1) 8 (20.5) 8 (20.5)
Moderate or Severe (11–21) 2 (5.1) 3 (7.7) 0 (0)
Enablement score (n = 113) (%) p = 0.000**
0 7 (18.4) 4 (10.5) 21 (56.8)
1-2 7 (18.4) 5 (13.2) 4 (10.8)
3-5 13 (34.2) 15 (39.5) 7 (18.9)
6-12 11 (28.9) 14 (36.8) 5 (13.5)
Analysis of the 6 week follow-up scores.
ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regression for HADs Depression and Enablement (n (%).
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who had no access to the website.Discussion
Summary of main findings
The trial has demonstrated that it is feasible to
recruit and randomise patients with IBS from many
GP practices to a complex trial and achieve high
follow-up rates.
The results must be interpreted with caution as this is
an exploratory study with relatively low numbers and
power. No statistically significant differences were seen
between the medication groups for the main outcome
measures (IBS SSS and IBS-QOL) at 6 or 12 weeks. Nor
were there any statistically significant differences between
the website groups for the IBS-QOL at 6 or 12 weeks or
IBS SSS at 12 weeks. However, there was a statisticallyTable 5 Main and secondary outcomes for medicine groups a
Variable Mebeverine
IBS-SSS total mean (n = 123) 183.3 (156.9-209.7)
IBS-QOL score (n = 123) 69.5 (65.7-73.4)
HADS score for anxiety (n = 114) 8.7 (7.7-9.7)
HADS score for depression (n = 114) (%)
Normal (0–7) 29 (30.9)
Mild (8–10) 3 (16.7)
Moderate or Severe (11–21) 2 (40.0)
Enablement score (n = 113)
0 6 (19.4)
1-2 5 (16.1)
3-5 9 (29.0)
6-12 11 (35.5)
Analysis of the 6 week follow-up scores.
ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regressionsignificant difference seen in the IBS SSS for the website
at 6 weeks, with the ‘no website’ group having a lower
IBS SSS score than the website groups, but this differ-
ence disappeared by 12 weeks.
There were no differences in the secondary outcomes
in the medicine groups.
In the website groups, there was significantly increased
Enablement at 6 and 12 weeks and a significantly more
participants scored Subjective Assessment of Global re-
lief (SGA) as improved at 12 weeks compared to the No
Website group.Strengths and limitations
This exploratory trial was the first to look at providing
CBT as a web-based self-management programme for
patients with IBS. The factorial design allowed the
feasibility of undertaking a trial to assess the effectivenesst six week follow up
Methylcellulose Placebo Significance
174.0 (149.7-198.4) 210.6 (185.6-235.5) p = 0.106
69.4 (65.8-73.0) 69.7 (66.0-73.3) p = 0.994
9.0 (8.1-9.9) 9.2 (8.3-10.1) p = 0.743
p = 0.590
36 (38.3) 29 (30.9)
5 (27.8) 10 (55.6)
0 (0) 3 (60.0)
p = 0.563
14 (35.9) 12 (27.9)
6 (15.4) 5 (11.6)
11 (28.2) 15 (34.9)
8 (20.5) 11 (25.6)
for HADs Depression and Enablement (n (%).
Table 6 Main and secondary outcomes for website groups at twelve week follow up
Variable Website Website + support No website group Significance
IBS-SSS total mean (n = 123) 207.9 (187.6 – 228.1) 193.4 (173.0- 213.8) 218.2 (197.4-238.9) p = 0.243
IBS-QOL score (n = 123) 71.6 (67.2 - 76.1) 69.5 (65.0 - 74.0) 64.3 (59.8 – 68.9) p = 0.068
HADS score for anxiety (n = 114) 8.8 (8.0- 9.7) 9.2 (8.3 -10.0) 8.0 (7.1 -8.8) p = 0.123
HADS score for depression (n = 114) (%) p = 0.981
Normal (0–7) 32 (84.2) 31 (79.5) 30 (81.1)
Mild (8–10) 6 (15.8) 4 (10.3) 4 (10.8)
Moderate or Severe (11–21) 0 (0) 4 (10.3) 3 (8.1)
Enablement score (n = 113) (%) p = 0.000**
0 7 (18.4) 4 (10.5) 21 (56.8)
1-2 7 (18.4) 5 (13.2) 4 (10.8)
3-5 13 (34.2) 15 (39.5) 7 (18.9)
6-12 11 (28.9) 14 (36.8) 5 (13.5)
SGA (%)
Responders 16 (45.7) 24 (63.2) 12 (32.4) p = 0.035*
Non responders 19 (54.3) 14 (36.8) 25 (67.6)
Analysis of the 12 week follow-up scores.
ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regression for HADs Depression, Enablement and SGA (n (%).
Everitt et al. BMC Gastroenterology 2013, 13:68 Page 10 of 13
http://www.biomedcentral.com/1471-230X/13/68of common IBS medications to be explored at the
same time.
Participants were asked to take 7 large over-encapsulated
tablets a day for 6 weeks. Despite this, compliance with the
medication taking was good.
The lack of difference between the medication groups
may be due to low power with the limited numbers in
this trial. A larger trial will be able to provide more
definitive results. Ideally, smaller trial medication would
be sourced for a larger trial to further improve compliance
and reduce the placebo effect of taking the tablets.Table 7 Main and secondary outcomes for medicine groups a
Variable Mebeverine
IBS-SSS total mean (n = 123) 203.1(181.3- 223.0)
IBS-QOL score (n = 123) 68.9 (64.1 – 73.6)
HADS score for anxiety (n = 114) 8.2 (7.3 – 9.1)
HADS score for depression (n = 114) (%)
Normal (0–7) 25 (78.1)
Mild (8–10) 5 (15.6)
Moderate or Severe (11–21) 2 (6.3)
Enablement score (n = 113)
0 6 (19.4)
1-2 5 (16.1)
3-5 9 (29.0)
6-12 11 (35.5)
SGA (%)
Responders 16 (57.1)
Non responders 12 (42.9)
ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal RegressionExpectancy effects (i.e. people's expectancy of web
treatment and drug treatment) and the placebo effect may
have influenced the trial results. We did not measure
treatment expectancy effects in this study.
Over 5700 patients were invited by their GP to participate
in this study with 135 being randomised. Thus a small
subset of the patients recorded as having IBS by their
GPs entered the study. This low recruitment rate is not
unexpected in a study requiring patients to be on no initial
medication, to take many large tablets a day and participate
in a self-management programme for 6 weeks, but it mayt twelve week follow up
Methylcellulose Placebo Significance
205.4 (185.3 -225.5) 210.9 (191.1 - 230.7) p = 0.865
66.3 (61.9 – 70.8) 70.2 (65.9 – 74.6) P = 0.453
8.7 (7.9- 9.6) 9.0 (8.2 -9.8) p = 0.422
P = 0.655
35 (89.7) 33 (76.7)
2 (5.1) 7 (16.3)
2 (5.1) 3 (7.0)
P = 0.231
14 (35.9) 12 (27.9)
6 (15.4) 5 (11.6)
11 (28.2) 15 (34.9)
8 (20.5) 11(25.6)
17 (43.6) 19 (44.2) P = 0.538
22 (56.4) 24 (55.8)
for HADs Depression, Enablement and SGA (n (%).
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affect the generalisability of the study findings. Reasons
for declining to enter the study have been sought and
recorded and the study sample is similar in gender and
age to the invited participants.
Comparisons with other studies
There are a limited number of published trials of CBT for
IBS but they indicate a positive effect for CBT on IBS over
a range of outcome measures [5,9,18,30] in the short-term
(up to 3 months). However, information is lacking for
longer term follow up. For instance, a trial of face to face
CBT plus mebeverine (6 × 50 minute CBT sessions over
6 week delivered by general practice nurses) against
mebeverine alone in a primary care setting in London [8]
showed a significant reduction in IBS-SSS in the CBT arm
at 3 months but not at 12 months follow up.
The lack of improvement in the IBS SSS and IBS-QOL
in the website self-management groups in this study
is disappointing as the paper-based self-management
programme from which the Regul8 website was developed
[20] did show a significant improvement in IBS SSS scores
in the self-management group compared to the control
group. It may be that an effect of the website was masked
by the general improvement in all groups during the
length of the trial. It is acknowledged in many trials that
IBS symptoms have a large placebo response to any
intervention and this can make it difficult to distinguish
true treatment effects, particularly in a small study.
However, we found a trend for continued improvement
in the self-management group (particularly those who
had the telephone support) whilst those in the No Website
group and the medication groups appeared to lose some
of these gains at 12 weeks (see Figures 2 and 3). Longer
term follow up may reveal differences between the website
groups. Two other reasons why the Regul8 programme
may be less successful than the paper-based manual are
that: the earlier study used an experienced therapist, and
had significantly more therapist contact time. In this study
a nurse with only minimal CBT training delivered the
intervention. In addition, of those that had access to the
Regul8 programme, half had no therapist support at all
and half had one, 30 min telephone support session,
whereas in the trial of the paper-based manual, one face
to face and two telephone support sessions were offered
to participants (3 hours in total). Therapist support is
expensive compared to a stand-alone website and thus
was deliberately kept to a minimum for this trial.
However, recently published trials of internet interven-
tions for IBS [18,30] and qualitative data from this study
suggest that it is important to assist engagement with the
website.
The finding that Enablement scores were higher in
those that had access to the Regul8 programme suggeststhat these participants felt better able to cope with their
symptoms. Additionally, those that received the telephone
session had higher Enablement than those with access to
the website without support. This suggests benefit from
the website which is enhanced by therapist support and
strengthens the postulation that the amount of support
offered in this study may have been insufficient. Ability to
cope with IBS symptoms and continue a full life is clearly
an important outcome irrespective of symptom severity.
Improvements in the Work and Social Adjustment Scale,
a measure of the ability to continue work and other
activities with IBS, was shown to be improved by
CBT in the long term (12 month follow up) in the
Kennedy trial [8].
The lack of any significant effect on IBS outcomes
in the medication arms of this study, may be due to
limited power, and would need to be confirmed in a
larger trial but are not unsurprising as a Cochrane
review [6] has highlighted the poor evidence of their
effectiveness.
Implications for future research and clinical practice
The factorial trial design for this study had the benefit of
providing data for both the medication and the website
groups but this may have limited the ability of the
trial to show an effect for the CBT self-management
programme, since the key to self-management is being
able to attribute symptom improvement to cognitive and
behavioural changes. In a blinded trial participants
would have had some difficulty knowing whether any
change in their symptoms was due to the medication
they were taking or to the CBT self-management
principles they were trying to employ. This issue was
raised in discussion with patients in the qualitative
interviews. The effect of including medication the
factorial design, may have been to reduce their confi-
dence in employing the CBT techniques. Thus a definitive
trial of the website should probably not include a blinded
medication component.
When recruiting participants from primary care for this
trial, it was found to be important to screen potential
participants with the ROME III and exclusion criteria as
98 of the 265 potential participants who completed the
screening questionnaire either did not fulfil the ROME
criteria or met exclusion criteria.
Conclusion
This study demonstrates that a trial of this type is feasible
in primary care and can be successfully completed with
robust trial procedures and high levels of follow up. A
larger trial (or trials) would have the power to determine
more definitive outcomes. Undertaking separate medicine
and website self-management programme trials is likely to
be appropriate in the larger trials. Increasing the therapist
Everitt et al. BMC Gastroenterology 2013, 13:68 Page 12 of 13
http://www.biomedcentral.com/1471-230X/13/68support sessions for the web-based self-management
programme would seem logical approach to try to further
increase patient enablement, which is an important aspect
of self-managing a chronic condition such as IBS.
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